Ligand Pharm (LGND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 51,812 | 41,531 | 30,978 | 28,101 | 32,868 |
| Cost of Goods | 2,449 | 2,906 | 2,882 | 1,641 | 3,485 |
| Gross Profit | 49,363 | 38,625 | 28,096 | 26,460 | 29,383 |
| Operating Expenses | 46,669 | 58,631 | 25,990 | 30,459 | 26,790 |
| Operating Income | 3,143 | -19,100 | 2,988 | -3,358 | 3,078 |
| Interest Expense | 741 | 1,268 | 141 | 131 | 1 |
| Other Income | -8,741 | -45,022 | 110,600 | 20,586 | -15,221 |
| Pre-tax Income | -6,339 | -65,390 | 113,447 | 17,097 | -12,144 |
| Income Tax | 833 | -13,479 | 27,308 | -1,091 | -1,871 |
| Net Income Continuous | -7,172 | -51,911 | 86,139 | 18,188 | -10,273 |
| Net Income | $-7,172 | $-51,911 | $86,139 | $18,188 | $-10,273 |
| EPS Basic Total Ops | -0.39 | -2.88 | 4.86 | 1.02 | -0.59 |
| EPS Basic Continuous Ops | -0.39 | -2.88 | 4.86 | 1.01 | -0.59 |
| EPS Diluted Total Ops | -0.39 | -2.88 | 4.75 | 1.07 | -0.59 |
| EPS Diluted Continuous Ops | -0.39 | -2.88 | 4.75 | 1.06 | -0.59 |
| EPS Diluted Before Non-Recurring Items | -0.39 | 0.92 | 0.80 | N/A | N/A |
| EBITDA(a) | $12,133 | $-10,581 | $11,680 | $6,142 | $11,341 |